|
Market Closed -
Nasdaq
02:30:01 21/11/2026 am IST
|
5-day change | 1st Jan Change | ||
| 0.2342 USD | -11.36% |
|
-23.46% | -98.72% |
| 17/11 | EyePoint, Inc. Presents at UBS Global Biopharma Conference 2026, Nov-17-2026 08:40 AM | |
| 13/11 | Stifel Adjusts Price Target on EyePoint Pharmaceuticals to $5 From $6, Keeps Buy Rating | MT |
| Market Cap | 2.66Cr 2.43Cr 2.24Cr 2.04Cr 3.82Cr 246.92Cr 4.02Cr 27Cr 11Cr 134.67Cr 10Cr 9.79Cr 423.3Cr | P/E 2026 * |
-0.06x | P/E 2027 * | -0.14x |
|---|---|---|---|---|---|
| Enterprise Value | -11Cr -10Cr -9.54Cr -8.66Cr -16Cr -1.05TCr -17Cr -115.63Cr -46Cr -572.89Cr -43Cr -42Cr -1.8TCr | EV / Sales 2026 * |
-53.6x | EV / Sales 2027 * | -225x |
| Free-Float |
97.33% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| EYPT | Delayed | |
| EYPT | Real-time | ||
| PV3B | Real-time | ||
| PV3B | Delayed | ||
| PV3B | Delayed | ||
| PV3B | Delayed | ||
| PV3B | Real-time |
Last Transcript: EyePoint, Inc.
| 1 day | -11.36% | ||
| 1 week | -23.46% | ||
| Current month | -32.78% | ||
| 1 month | -45.53% | ||
| 3 months | -95.60% | ||
| 6 months | -98.17% | ||
| Current year | -98.72% |
| 1 week | 0.23 | 0.32 | |
| 1 month | 0.23 | 0.43 | |
| Current year | 0.23 | 18.87 | |
| 1 year | 0.23 | 19.11 | |
| 3 years | 0.23 | 30.99 | |
| 5 years | 0.23 | 30.99 | |
| 10 years | 0.23 | 39.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jay Duker
CEO | Chief Executive Officer | 67 | 10/07/2023 |
George Elston
DFI | Director of Finance/CFO | 61 | 14/11/2019 |
Ramiro Ribeiro
CTO | Chief Tech/Sci/R&D Officer | 43 | 04/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jay Duker
BRD | Director/Board Member | 67 | 10/07/2023 |
| Chairman | 77 | 10/09/2018 | |
John Landis
BRD | Director/Board Member | 73 | 25/10/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 20/08/26 | Others | Chief Financial Officer | -1,39,906 | 0.1669% | ||
| 18/08/26 | Buy | Director | 10,600 | 0.0126% | ||
| 10/07/26 | Exercice | Chief Executive Officer | 41,393 | 0.0494% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -11.36% | -23.46% | -98.29% | -96.17% | 2.66Cr | ||
| -0.30% | -6.68% | +27.12% | +127.32% | 1,20000Cr | ||
| +1.25% | -5.35% | +32.65% | +78.98% | 65TCr | ||
| +0.94% | -2.99% | +21.13% | +106.30% | 51TCr | ||
| -0.60% | -1.95% | +25.73% | +67.00% | 38TCr | ||
| +0.69% | -9.50% | +36.78% | +30.83% | 33TCr | ||
| +0.41% | -4.70% | +24.18% | +50.18% | 29TCr | ||
| +0.81% | -4.08% | -2.95% | +31.59% | 27TCr | ||
| -0.15% | -6.45% | +29.06% | +65.76% | 24TCr | ||
| -0.06% | -0.98% | +31.42% | +122.83% | 21TCr | ||
| Average | -0.84% | -6.63% | +12.68% | +58.46% | 41TCr | |
| Weighted average by Cap. | +0.30% | -5.19% | +26.02% | +87.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 21.16L 19.28L 17.79L 16.16L 30.33L 20Cr 31.89L 2.16Cr 85.87L 11Cr 79.37L 77.7L 34Cr | 9L 8L 8L 7L 13.16L 8.51Cr 13.84L 93.64L 37.26L 4.64Cr 34.44L 33.72L 15Cr |
| Net income | -34Cr -31Cr -28Cr -26Cr -48Cr -3.13TCr -51Cr -344.28Cr -136.99Cr -1.71TCr -126.63Cr -123.96Cr -5.36TCr | -19Cr -18Cr -16Cr -15Cr -28Cr -1.79TCr -29Cr -196.56Cr -78Cr -973.86Cr -72Cr -71Cr -3.06TCr |
| Net Debt | -14Cr -13Cr -12Cr -11Cr -20Cr -1.3TCr -21Cr -142.81Cr -57Cr -707.56Cr -53Cr -51Cr -2.22TCr | -23Cr -21Cr -20Cr -18Cr -33Cr -2.16TCr -35Cr -237.75Cr -95Cr -1.18TCr -87Cr -86Cr -3.7TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/26/20 | $0.2342 | -11.36% | 49,38,937 |
| 19/26/19 | $0.2642 | -2.87% | 34,47,525 |
| 18/26/18 | $0.2720 | -8.08% | 36,10,328 |
| 17/26/17 | $0.2959 | -3.80% | 45,76,326 |
| 16/26/16 | $0.3076 | +0.52% | 65,46,986 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- EYPT Stock
Select your edition
All financial news and data tailored to specific country editions
















